Short answer
FATE THERAPEUTICS INC (FATE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). ATM equity program authorizes up to $100 million in common-stock sales, providing Fate with flexible funding access.
FATE THERAPEUTICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM equity program authorizes up to $100 million in common-stock sales, providing Fate with flexible funding access
- Share issuance remains discretionary, limiting immediate dilution but creating potential dilution if capital is raised
- Leerink Partners commission up to 3.0% of gross proceeds, reducing net cash raised
- Existing S-3 expires November 27, 2026, with planned replacement registration enabling continued sales through May 26, 2027
Item 1.02 · Termination of a Material Definitive Agreement
- Jefferies ATM agreement terminated November 5, 2026, replaced in connection with a new Sales Agreement
- 2,801,602 shares sold for $8.0 million gross proceeds under the terminated facility
- No termination penalties, eliminating obligations under the Jefferies arrangement
- Former facility allowed up to $100.0 million in common-stock sales, but remaining capacity is no longer usable
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FATE THERAPEUTICS INC 8-K filings
Get the next FATE 8-K as it lands
Follow FATE for push alerts, or ask the research agent what this filing means.